These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 15640842)

  • 21. Polo box domain of Plk3 functions as a centrosome localization signal, overexpression of which causes mitotic arrest, cytokinesis defects, and apoptosis.
    Jiang N; Wang X; Jhanwar-Uniyal M; Darzynkiewicz Z; Dai W
    J Biol Chem; 2006 Apr; 281(15):10577-82. PubMed ID: 16478733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current assessment of polo-like kinases as anti-tumor drug targets.
    Craig SN; Wyatt MD; McInnes C
    Expert Opin Drug Discov; 2014 Jul; 9(7):773-89. PubMed ID: 24819909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer.
    Kressin M; Fietz D; Becker S; Strebhardt K
    Cells; 2021 May; 10(5):. PubMed ID: 34065956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crystal structure of the polo-box domain of polo-like kinase 2.
    Shan HM; Wang T; Quan JM
    Biochem Biophys Res Commun; 2015 Jan; 456(3):780-4. PubMed ID: 25511705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Acidophilic Kinases PLK2 and PLK3: Structure, Substrate Targeting and Inhibition.
    Cozza G; Salvi M
    Curr Protein Pept Sci; 2018; 19(8):728-745. PubMed ID: 29366414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Finding Plk3.
    Zimmerman WC; Erikson RL
    Cell Cycle; 2007 Jun; 6(11):1314-8. PubMed ID: 17568195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation on PLK2 and PLK3 substrate recognition.
    Salvi M; Trashi E; Cozza G; Franchin C; Arrigoni G; Pinna LA
    Biochim Biophys Acta; 2012 Dec; 1824(12):1366-73. PubMed ID: 22828320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Schistosoma mansoni Polo-like kinases and their function in control of mitosis and parasite reproduction.
    Dissous C; Grevelding CG; Long T
    An Acad Bras Cienc; 2011 Jun; 83(2):627-35. PubMed ID: 21670883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hormonal induction of polo-like kinases (Plks) and impact of Plk2 on cell cycle progression in the rat ovary.
    Li F; Jo M; Curry TE; Liu J
    PLoS One; 2012; 7(8):e41844. PubMed ID: 22870256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell-cycle control: POLO-like kinases join the outer circle.
    Lane HA; Nigg EA
    Trends Cell Biol; 1997 Feb; 7(2):63-8. PubMed ID: 17708908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer.
    Zeng Y; Li N; Liu W; Zeng M; Cheng J; Huang J
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2447-2460. PubMed ID: 32627077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic inactivation implies a tumor suppressor function in hematologic malignancies for Polo-like kinase 2 but not Polo-like kinase 3.
    Smith P; Syed N; Crook T
    Cell Cycle; 2006 Jun; 5(12):1262-4. PubMed ID: 16868416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polo-like kinases in cell cycle checkpoint control.
    Dai W; Huang X; Ruan Q
    Front Biosci; 2003 Sep; 8():d1128-33. PubMed ID: 12957816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics.
    Gao Y; Kabotyanski EB; Shepherd JH; Villegas E; Acosta D; Hamor C; Sun T; Montmeyor-Garcia C; He X; Dobrolecki LE; Westbrook TF; Lewis MT; Hilsenbeck SG; Zhang XH; Perou CM; Rosen JM
    Cancer Res Commun; 2021 Dec; 1(3):178-193. PubMed ID: 35156101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polo-like kinase 3 is required for entry into S phase.
    Zimmerman WC; Erikson RL
    Proc Natl Acad Sci U S A; 2007 Feb; 104(6):1847-52. PubMed ID: 17264206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polo-like kinases inhibited by wortmannin. Labeling site and downstream effects.
    Liu Y; Jiang N; Wu J; Dai W; Rosenblum JS
    J Biol Chem; 2007 Jan; 282(4):2505-11. PubMed ID: 17135248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of polo-like kinase 1 in carcinogenesis: cause or consequence?
    Cholewa BD; Liu X; Ahmad N
    Cancer Res; 2013 Dec; 73(23):6848-55. PubMed ID: 24265276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polo-like kinases (plks), a key regulator of cell cycle and new potential target for cancer therapy.
    Lee SY; Jang C; Lee KA
    Dev Reprod; 2014 Mar; 18(1):65-71. PubMed ID: 25949173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies.
    Syed N; Smith P; Sullivan A; Spender LC; Dyer M; Karran L; O'Nions J; Allday M; Hoffmann I; Crawford D; Griffin B; Farrell PJ; Crook T
    Blood; 2006 Jan; 107(1):250-6. PubMed ID: 16160013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. From Plk1 to Plk5: functional evolution of polo-like kinases.
    de Cárcer G; Manning G; Malumbres M
    Cell Cycle; 2011 Jul; 10(14):2255-62. PubMed ID: 21654194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.